Physician profile
Jonathan Fellows
NPI 1376513655
$163,547.55
in general payments reported to CMS, 2019-2025
35 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $15K · 2021: $45K · 2022: $13K · 2023: $18K · 2024: $23K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,910 · Food and Beverage: $4,041 · Travel and Lodging: $3,702 · Consulting Fee: $1,183 · Education: $23.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,720.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,910.00 |
| Food and Beverage | $4,041.49 |
| Travel and Lodging | $3,702.23 |
| Consulting Fee | $1,182.50 |
| Education | $23.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57,501.63 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Abbvie INC. | $39,602.20 | 2021-2024 | |
| Biogen, INC. | $27,522.68 | 2019-2024 | Spinraza |
| Eisai INC. | $21,627.98 | 2022-2025 | |
| Allergan, INC. | $15,006.84 | 2019-2021 | |
| Amgen INC. | $329.19 | 2024-2025 | Uplizna |
| Tg Therapeutics, INC. | $219.46 | 2023-2024 | |
| Pfizer INC. | $193.72 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $192.78 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $165.88 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Ucb, INC. | $163.61 | 2022-2024 | Briviact |
| Emd Serono, INC. | $128.94 | 2019-2020 | |
| Genentech USA, INC. | $105.95 | 2023-2024 | Ocrevus, Enspryng |
| Corium, LLC | $100.90 | 2023-2024 | Adlarity, Azstarys |
| Sumitomo Pharma America, INC. | $86.82 | 2024 | Aptiom |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $83.51 | 2022-2023 | Zeposia |
| Horizon Therapeutics Plc | $80.02 | 2023 | Uplizna |
| Lundbeck LLC | $62.86 | 2023-2024 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $59.63 | 2023-2024 | Gammagard, Hyqvia |
| Genzyme Corporation | $55.40 | 2019-2023 | |
| Grifols USA, LLC | $36.69 | 2024 | Gamunex-C |
| Sk Life Science, INC. | $19.79 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.55 | 2024 | Keveyis |
| Alexion Pharmaceuticals, INC. | $18.67 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.24 | 2022 | |
| Cadwell Industries, INC | $18.01 | 2019 | |
| Acadia Pharmaceuticals INC | $17.70 | 2024 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $17.49 | 2023 | |
| Neurelis, INC. | $16.29 | 2022 | |
| Impel Pharmaceuticals INC. | $15.90 | 2022 | |
| Scilex Pharmaceuticals INC. | $15.49 | 2024 | |
| Acorda Therapeutics, INC | $15.44 | 2023 | Inbrija |
| Otsuka America Pharmaceutical, INC. | $15.02 | 2023 | Nuedexta |
| Alnylam Pharmaceuticals INC. | $13.27 | 2023 | Onpattro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Fellows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.